Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > latent GDF-8

latent GDF-8

Brief Information

Name:Growth/differentiation factor 8
Target Synonym:MSTN,GDF-8,GDF8,Growth Differentiation Factor 8,MSLHP,Myostatin,Growth/Differentiation Factor 8
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:4
Lastest Research Phase:Phase 3 Clinical

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
GD8-H5243 Human Human latent GDF-8 Protein, His Tag (MALS verified)
ACRO Quality

Part of Bioactivity data

latent GDF-8 MALS images

The purity of Human latent GDF-8, His Tag (Cat. No. GD8-H5243) is more than 90% and the molecular weight of this protein is around 80-95 kDa verified by SEC-MALS.

Synonym Name

latent GDF-8, GDF-8, Myostatin, GDF8, MSTN, Growth/differentiation factor 8


Growth differentiation factor 8 (GDF8), also known as myostatin, is a unique member of the transforming growth factor-β superfamily that is expressed in human granulosa cells and has important roles in regulating a variety of ovarian functions. GDF8 acts as a negative regulator of skeletal muscle growth and differentiation. In addition to the expression in the musculoskeletal system, GDF8 is also expressed in various tissues, including the reproductive system.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Apitegromab SRK-015 Phase 3 Clinical Scholar Rock Spinal Muscular Atrophies of Childhood; Neuromuscular Manifestations; Muscular Atrophy; Neuromuscular Diseases; Muscular Atrophy, Spinal; Atrophy Details
AAV1-FS344 AAV1-Follistatin; AAV1-FS344 Phase 2 Clinical Nationwide Children'S Hospital Myositis, Inclusion Body; Muscular Dystrophy, Duchenne Details
Talditercept alfa RO-7239361; BMS-986089; RG-6206; BHV-2000 Phase 3 Clinical Bristol-Myers Squibb Company Muscular Dystrophy, Duchenne; Neuromuscular Diseases; Muscular Atrophy, Spinal Details
RO-7204239 GYM-329; RO-7204239; RG-6237; RG-70240 Phase 3 Clinical F. Hoffmann-La Roche Ltd, Chugai Pharmaceutical Co Ltd Muscular Dystrophy, Facioscapulohumeral; Muscular Atrophy, Spinal Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message